Table 2 Characteristics of the included studies
First Author | Country | Year | Sample size | Mean age (Range/ Years) | Study design | Types of MRI Sequences | Name of scanner | Initial clinical stage | Subtype of Cancer | Histology subtype | Evaluation index | Lesion size (mm) | Type of NAC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sekine (11) | Japan | 2021 | 74 | 48 (30‑78) | Retrospective | T1-weighted sequence (T1W), T2-weighted sequence (T2W), along with dynamic contrast-enhanced imaging, | a-Se full-field digital mammography (FFDM) system with a spatial resolution of 85 μm (MAMMOMAT Inspiration, Siemens) | T1 (13), T2 (48), T3 (11), T4 (2) | HR+/HER2 (30), HR+/HER2+ (16), HR/HER2+ (10), HR/HER2 (18) | IDC (71), ILC (1), Metaplastic carcinoma (2) | FFDG PET/MRI | 0.36 | Most patients (72 out of 74) were treated with an anthracycline-based regimen followed by a taxane regimen. For patients with HER2-positive disease, the NAC regimen was augmented with targeted therapies: All patients with HER2-positive disease received trastuzumab as part of their treatment. One patient with HER2-positive disease also received pertuzumab in addition to trastuzumab. Two patients received a platinum-based regimen followed by a taxane regimen, which included: |
Umutlu (12) | Germany | 2022 | 73 | 49 (Range 27–77 years) | Retrospective | T2-weighted fat-saturated TSE, diffusion-weighted EPI, and dynamic contrast-enhanced T1-weighted FLASH. | Biograph mMR, Siemens Healthcare GmbH, Erlangen, Germany | G1 (1), G2 (37), G3 (35) | Basal-like/ triple-negative (19), Luminal A (10), Luminal B (42), Her2-enriched (2) | NST (69), Lobular invasive (3), Other (1) | 18 F-FDG PET/MRI MRI PET | NR | |
Cho (13) | Republic of Korea | 2017 | 26 | 42.2 | Prospective | axial Dixon-VIBE and coronal HASTE. | Biograph mMR; Siemens Healthcare, Erlangen, Germany | II (5), III (21) | Hormone receptor-positive (15), Triple-negative (4), HER2-positive (7) | 18 F-FDG PET/MRI MRI PET | 0.49 | For HER2-Negative Disease: NAC Regimen: Combination of anthracyclines and taxanes. For HER2-Positive Disease: NAC Regimen: Chemotherapy incorporating HER2-targeted agents (e.g., trastuzumab and/or pertuzumab). | |
de Mooij (14) | Netherlands | 2022 | 10 | 50.3 | Prospective | unenhanced T1-weighted (T1W), unenhanced T2-weighted (T2W), and the PET sequence. | Siemens Healthcare, Erlangen, Germany | I (1), II (5), III (4) | ER (6), PR (4), HER2 (5) | NST (9), Mixed NST, and ILC (1) | 18 F-FDG PET/MRI T1-weighted imaging T2-weighted imaging PET | For HER2-Negative Patients: Option 1: Taxanes (docetaxel or paclitaxel) followed by epirubicin and cyclophosphamide, with or without fluorouracil. Option 2: Fluorouracil, epirubicin, and cyclophosphamide (or epirubicin and cyclophosphamide) followed by taxanes. For HER2-Positive Patients: Option 1: Taxanes in combination with trastuzumab, followed by fluorouracil, epirubicin, and cyclophosphamide (or epirubicin and cyclophosphamide). Option 2: Concurrent regimen of taxanes, cyclophosphamide, trastuzumab, and pertuzumab.Option 3: Carboplatin in combination with taxanes, trastuzumab, and pertuzumab. | |
Wang (15) | Taiwan | 2017 | 14 | 54.5 | NR | 10 sequences (3 precontrast, 6 DCE-MRI postcontrast, 1 MRS) PET Sequences: 1 main sequence for breast PET imaging with attenuation correction | - | T1 (1), T2 (11), T3 (2) | Lum A (2), Lum B (1), HER2 positive (8), TNBC (3) | PET/MR(SUVmax/ADCmin) PET/MR (TLG/ADCmin) | 0.36 | For HER2-Negative Patients: Option 1: Taxanes (docetaxel or paclitaxel) followed by epirubicin and cyclophosphamide, with or without fluorouracil.Option 2: Fluorouracil, epirubicin, and cyclophosphamide (or epirubicin and cyclophosphamide) followed by taxanes. For HER2-Positive Patients: Option 1: Taxanes in combination with trastuzumab, followed by fluorouracil, epirubicin, and cyclophosphamide (or epirubicin and cyclophosphamide). Option 2: Concurrent regimen of taxanes, cyclophosphamide, trastuzumab, and pertuzumab. Option 3: Carboplatin in combination with taxanes, trastuzumab, and pertuzumab. | |
de Mooij (16) | Netherlands | 2023 | 42 | 50 | Prospective | Axial DWI (EPI and CHESS) Pre-contrast dynamic contrast-enhanced axial T1WI (VIBRANT and CHESS) Post-contrast dynamic contrast-enhanced axial T1WI (90 s phase) Post-contrast dynamic contrast-enhanced axial T1WI (180 s phase) Post-contrast dynamic contrast-enhanced axial T1WI (270 s phase) | Biograph mMR; Siemens Healthineers, Erlangen, Germany | I (4), II (22), III (16) | ER+/HER2- (19), ER+/HER2+ (7), ER-/HER2+ (6), TNBC (10) | 18 F-FDG PET/MRI MRI PET | 0.34 | For ER-Positive and/or HER2-Positive Breast Cancer: Initial Regimen: 4 cycles of doxorubicin and cyclophosphamide, administered every 3 weeks. Subsequent Regimen: 4 cycles of docetaxel, administered every 3 weeks. Targeted Therapy: For HER2-positive cases, trastuzumab was included in the regimen. Additionally, one or more patients received pertuzumab along with trastuzumab. For Triple-Negative (TN) Breast Cancer: Regimen: 12 cycles of weekly doses of paclitaxel. |